Skip to main content
Oregon.gov Homepage

COVID-19 Healthcare Partner Resources



COVID-19 Vaccine Information

Documents

 Oregon's COVID-19 Vaccination Plan
 Phase 1a Vaccine Sequencing Plan
 Phase 1a Sequencing Update - 1/5/2021
 Phase 1a FAQ
 General Vaccine FAQ

Reports

Data

OHA COVID-19 Website

FAQs by Topic

COVID-19 News from OHA

Sign up for Coronavirus Updates

Contact Us

Pandemic Resources

Bamlanivimab (Eli Lilly and Company)​

​

On November 9, 2020, the Food and Drug Administration released an Emergency Use Authorization (EUA) for the release of Eli Lilly and Company's monoclonal antibody therapy, Bamlanivimab, for the treatment of test-confirmed COVID-19 positive patients (adults and children aged greater than 12 years of age and >40kg) with mild to moderate disease. The EUA only includes the treatment ​of​​ non-hospitalized COVID-19 patients with high-risk factors including:

  • Age > 65 years
  • Obesity with BMI > 35 and
  • High risk conditions including diabetes, chronic kidney disease, coronary artery disease, hypertension and others

Full eligibility criteria is available here in Fact Sheet for Healthcare Providers.​

Bamlanivimab should be refrigerated and administered by trained personnel as a single dose infusion of 700mg in the first 10 days after symptom onset in confirmed cases only. Additionally, the requirements of the EUA include that it be administered in settings where providers will be able to monitor for severe side effects including anaphylaxis and can activate emergency medical services as necessary.

The considerations for distribution of this drug include:

  • Space: Dedicated space to treat COVID-19 positive patients with appropriate precautions at facilities equipped to provide infusions
  • Refrigeration: required at 2-8 degrees.
  • Supplies: Simple IV supplies. Can be given by gravity or pump.
  • Staff: Nurse, IV tech with support from physician and pharmacist.
  • Scheduling: infusion time is 1-hour, plus an additional 1-hour post-infusion observation period is required.
  • Reporting: required for adverse events
  • Billing/reimbursement: once commercially available, there could be significant costs for purchasing and administration. While the product is available at no cost in this period, the Medicare payment rate for the infusion of the Bamlanivimab product, will be $309.60. Additional details found on the Medicare Antibody Infusion Program Instruction.

Resources

​

Casirivimab and Imdevimab (Regeneron Pharmaceuticals)

​

On November 21, 2020, the Food and Drug Administration released an Emergency Use Authorization (EUA) for the release of Regeneron Pharmaceuticals' monoclonal antibody therapy, Casirivimab and Imdevimab, for the treatment of test-confirmed COVID-19 positive patients (adults and children aged greater than 12 years of age and >40kg) with mild to moderate disease. The EUA only includes the treatment of non-hospitalized COVID-19 patients with high-risk factors including:

  • Age > 65 years
  • Obesity with BMI > 35 and
  • High risk conditions including diabetes, chronic kidney disease, coronary artery disease, hypertension and others

Full eligibility criteria is available here in Fact Sheet for Healthcare Providers

Casirivimab and Imdevimab should be refrigerated and administered by trained personnel. Although they are packaged separately, casirivimab and imdevimab must be administered together after dilution by single intravenous (IV) infusion only The two products are available in single dose vials of 300mg/2.5ml and 1332mg/11.1ml and should be combined before infusion to include about 1200mg of each product administered together, within the first 10 days after symptom onset in confirmed cases only. Additionally, the requirements of the EUA include that it be administered in settings where providers will be able to monitor for severe side effects including anaphylaxis and can activate emergency medical services as necessary.

The considerations for distribution of this drug include:

  • Space: Dedicated space to treat COVID-19 positive patients with appropriate precautions at facilities equipped to provide infusions
  • Refrigeration: required at 2-8 degrees.
  • Supplies: Simple IV supplies. Can be given by gravity or pump.
  • Staff: Nurse, IV tech with support from physician and pharmacist.
  • Scheduling: infusion time is 1-hour, plus an additional 1-hour post-infusion observation period is required.
  • Reporting: required for adverse events
  • Billing/reimbursement: CMS is providing up to the minute instructions on coding and billing for the infusion of these products. Updated guidance can be found on the CMS website and provided additionally as a link below.

Resources

Oregon Resources

​

Federal Resources

Veklury® (remdesivir)

Resources

​

Public Readiness and Emergency Preparedness Act (PREP Act)​

The federal Public Readiness and Emergency Preparedness Act (PREP Act) provides liability protections for “covered persons" involved in many aspects of the COVID-19 response.  

Read more about the PREP Act


Playbooks describe the joint collaborative agreement between the Oregon Health Authority, COVID-19 Response and Recovery Unit and other state agencies with the intended goal of stabilizing the spread of a COVID-19 outbreak in a facility or work place. The Playbooks describe the roles and responsibilities of each agency and program as stabilization efforts are coordinated.

Responding to Outbreaks in Agriculture and Farm Operations

The purpose of this plan is to establish the coordination and response efforts of the Oregon Occupational Safety and Health Administration (Oregon OSHA), Oregon Department of Agriculture (ODA), and the Oregon Health Authority (OHA) when one or more cases of COVID19 are identified at a farming operation.

Responding to Outbreaks in a Child Welfare Setting

The document below establishes the coordination and response efforts of the Department of Human Services (ODHS) and Oregon Health Authority (OHA) when one or more positive COVID-19 cases is reported in a facility.

Responding to Outbreaks in Developmental Disability Residential Settings

The document below establishes the coordination and response efforts of the Department of Human Services Office of Developmental Disabilities Services (ODDS) and Oregon Health Authority (OHA) when three or more cases of COVID-19 are associated with a developmental d​isability residential setting, otherwise known as a facility.

Responding to Outbreaks in Emergency Child Care Setting

The document below establishes the coordination and response efforts of the Early Learning Division (ELD), Office of Child Care (OCC), Oregon Department of Education (ODE), Oregon Department of Human Services (ODHS) and Oregon Health Authority (OHA) when one or more cases of COVID-19 are identified in an Emergency Child Care Setting.

Responding to Outbreaks in Houseless Services Settings

The document below establishes the coordination and response efforts of the Local Public Health Authority (LPHA), COVID Response and Recovery Unit (CRRU), Oregon Department of Human Services (ODHS) and the Oregon Health Authority (OHA) when there is an outbreak in a houseless services setting.

Responding to Outbreaks in Long Term Care Facilities

The document below establishes the coordination and response efforts of the Department of Human Services (DHS), Aging and People with Disabilities (APD) and Oregon Health Authority (OHA) when three (3) or more cases of COVID-19 are associated with a long-term care facility. This coordinated response will help to prevent and slow the spread of COVID-19 and, when it is possible, ensure that these facilities can continue to operate while protecting the public’s health. This coordinated agreement allows for proactive strategies to prevent further spread within in a facility.

​​
​
​
​

COVID-19 Vaccine Provider Enrollment

The Oregon Health Authority is beginning phased enrollment of healthcare providers who wish to administer COVID-19 vaccine. The following provider types may begin enrollment now:

  • Tribes and Tribal health authorities
  • Local public health authorities
  • Hospitals

Additional provider types will be allowed to enroll at a later date and should check back frequently for updated information.

Providers wanting to administer COVID-19 vaccine must be fully enrolled through the online enrollment system.

  • To be fully enrolled, the online enrollment system will require providers to register for ALERT IIS and to specifically sign up to receive COVID-19 vaccine.
  • Providers experiencing difficulties or who have questions about the enrollment process may email the Oregon Health Authority's provider enrollment team: Vaccine.ProviderEnroll@dhsoha.state.or.us. Please include your provider type in the subject heading of the email to help us triage our responses.

PDF forms will not be accepted at this time to streamline the process as much as possible. We have provided PDF copies of the enrollment information here to help you prepare to use the online enrollment system.


Vaccine Distribution Plan

​The CDC has asked all states to share how they plan to distribute COVID-19 vaccine once a safe and effective vaccine is ready. OHA has submitted a draft plan to CDC. OHA’s plan will follow federal guidance for a phased approach. This means starting with vaccinations for critical groups, including people involved in the pandemic response and people at the highest risk for getting very sick. As more vaccine becomes available, there will be wider distribution to other high risk groups and the general public.

CDC, CVS and Walgreens Vaccination Program

For skilled nursing, assisted living, residential care, adult foster care and other community-based care facilities, such as group homes for people with intellectual and developmental disabilities

Oregon Department of Human Services and Oregon Health Authority are notifying long-term care facilities and small congregate settings that their residents and employees can get no-cost COVID-19 vaccinations when a vaccine becomes available. 

The registration deadline for this program has passed​.

More: COVID-19 Vaccine Information for Providers

​

For Oregon Healthcare Personnel, Partners and Local Public Health

Guidance for Dental Providers

In School Settings

Parent Handouts

Below are handouts that dental providers can provide to parents on coronavirus and oral health, from the National Maternal and Child Oral Resource Center website.

COVID-19 EMS Protocols

Prehospital Guidance for COVID-19

Healthcare Exposure and Work Exclusion

OR-EMSIS Data Collection

Ambulance Reimbursement Policy Changes

Management of COVID-19 in Correctional and Detention Facilities

Administering Naloxone During COVID-19

​

Webinars

Mask and Face Covering Use in Health Care Offices

​

COVID-19 Testing

Testing Guidance

​

NOTE: Clinicians throughout the community can order COVID-19 testing at their discretion through commercial labs WITHOUT approval by public health.

To Get Approval for Testing through the Oregon State Public Health Laboratory

COVID-19 Testing Labs

Clinical and Infection Control Guidance

Guidance for Clinics, Hospitals and Long-Term Care Facilities

CDC Guidance for Clinics and Hospitals

Specific Guidance for Long-Term Care Facilities

Foster Care or Group Homes

Workers Providing In-home Personal Care

In-person interpreters and health care providers who work with them

Correctional and Detention Facilities

Home Care​

​
​

Admissions and Readmissions

Entry into Acute Health Care Facilities

​

Elective and Non-Urgent Procedures

Governor's Executive Order 20​-22

Framework for Restarting

Workgroup on PPE Guidance for Non-Emergency and Elective Procedures

Resumption and Continued Provision of Non-Emergent and Elective Procedures

​

Influenza Testing and COVID-19

Clients with Suicide Risk

Traditional Health Workers

Non-discrimination in Medical Treatment

Disease Reporting

Submitting Specimens to OSPHL

Obtain approval for testing through the Oregon State Public Health Laboratory by submitting a Confidential Oregon Morbidity Report​ (see Provisional Guidance for details).

Specimens approved for testing should be shipped refrigerated (2-8°C) to the Oregon State Public Health Laboratory (OSPHL) following appropriate shipping regulations.

    The following completed form must accompany all specimens:
  • Virology/Immunology Test Request Form (one form per specimen)
    • In the “OTHER/MOLECULAR” section, mark the checkbox indicating “Other” and type or write in “2019-nCoV” or “COVID-19” on the line provided.

Please refer to the OSPHL Lab Test Menu and the CDC Interim Guidance for Collecting, Handling, and Testing Clinical Specimens from PUIs for complete specimen collection guidance.

COVID-19 Training: TRAIN Learning Network

CDC TRAIN provides access to courses developed by the Centers for Disease Control and Prevention (CDC) programs, grantees, and other funded partners. Courses offered by CDC course providers have been approved and verified by CDC.

Ambulatory practice questions?

Email cccoperations@ohsu.edu.

​

​

Behavioral Health Resources for Responders​

This is a non-exhaustive list of available behavioral health supports. Some of the resources are for individuals actively seeking support for themselves and are also useful for organizational and governmental leaders if signs of stress or burnout are apparent in staff and volunteers. ​

​ ​​

Investigative Guidelines

​

Surge Condition Protocol


Letter Templates

Case Letter

Contact Letter

ADA Guidance

Isolation and Quarantine Processes

Risk Communication

PPE Requests

​

Laboratory-related Terminology and Training

Ready Schools, Safe Learners LPHA Webinar

Guidance for Pharmacies

Visit the Oregon Board of Pharmacy website for the most recent gui​dance.

COVID-19 Information Sessions for Oregon Health Care Providers

Thursdays at noon

 ECHO Informational Sessions Flyer   Informational Sessions Survey

Microsoft Teams Live Event (audio provided through computer or mobile device), 2nd Thursday of each month

2021 webinar schedule

View past material (pdf)

2020

These documents can be provided upon request in alternate formats for individuals with disabilities or in a language other than English for people with limited English skills. To request this publication in another format or language, email thomas.cogswell@dhsoha.state.or.us, or call 971-304-9642 (voice) or 711 for TTY.

Watch the recordings (YouTube)

2020
​​​​​​​​​​​​​​​

This virtual interactive session occurs on the 2nd and 4th Thursday from 12-1:15 pm. Hosted by the Oregon ECHO Network at OHSU, the session will be staffed by Dr. Hargunani and Dr. Jennifer Vines, Multnomah County Health Officer and other invited content experts. They will provide the latest updates, share COVID-19 clinical cases and answer questions.

​Register for the full series

View past material (pdf)

2021

2020

Watch the recordings (Vimeo)

2020

Mask and Face Covering Use in Health Care Offices

COVID-19 Data and Reports

 OHA COVID-19 Website   COVID-19 Data Dashboards

Data Reports and Projections


REALD Data Collection

Starting October 1, 2020, health care providers subject to Oregon Disease Reporting rules must report REALD information when reporting the following information to the Oregon Health Authority (OHA):

  • Positive or negative COVID-19 cases,
  • COVID-19 hospitalizations or deaths, and
  • MIS-C cases.

View OHA's fact sheet that describes which providers must start reporting on October 1, 2020 and March 1, 2021.

Phase 1 providers who cannot start reporting data on October 1, 2020, must submit a compliance plan to OHA by December 31, 2020.

REALD for Health Care Providers



Your browser is out-of-date! It has known security flaws and may not display all features of this and other websites. Learn how

×